TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23239679

Group type: EXPERIMENTAL
Intervention: Chicken noodle soup (355 ml)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water (355 ml)
Number of subjects: 9
Study: 21676280

Group type: EXPERIMENTAL
Intervention: HFHC meal (14,644 kJ/d; 3500 kcal/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dietary Reference Intake (10878.4 kJ/d; 2600 kcal/d)
Number of subjects: 10
Study: 18178494

Group type: EXPERIMENTAL
Intervention: CIC640 (640 microg/day)
Number of subjects: 680

Group type: COMPARATOR
Intervention: CIC160 (160 microg/day)
Number of subjects: 680
Study: 16411983

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day (increased to 10 mg/day after 4 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Donepezil and Placebo
Number of subjects: 12
Study: 12921494

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5mg
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 2.5mg
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 1mg
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 0.5mg
Number of subjects: 1093
Study: 12585821

Group type: EXPERIMENTAL
Intervention: computer treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: control group
Number of subjects: 10
Study: 9702935

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 360

Group type: COMPARATOR
Intervention: Felodipine ER
Number of subjects: 360
Study: 7859632

Group type: EXPERIMENTAL
Intervention: Nisei women with IGT at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nisei men with IGT at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nisei women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nisei men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Japanese Americans with IGT and NIDD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIDD
Number of subjects: 0
Study: 2690065

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study: 31079082

Group type: EXPERIMENTAL
Intervention: VMSCC service (usual care plus access to a tablet with 30 videos, monthly communication with a registered nurse, regular blood pressure monitoring)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: VMSCC service
Number of subjects: 384
Study: 28591387

Group type: EXPERIMENTAL
Intervention: Sublingual atropine sulfate
Number of subjects: 25
Study: 25855680

Group type: EXPERIMENTAL
Intervention: SYNERGY stent
Number of subjects: 1684

Group type: COMPARATOR
Intervention: PROMUS Element Plus stent
Number of subjects: 1684
Study: 23726334

Group type: EXPERIMENTAL
Intervention: Tooth sealant polish (Biscover LV; Bisco, Schaumberg, Ill) applied to maxillary anterior teeth
Number of subjects: 62

Group type: COMPARATOR
Intervention: No sealant applied to control teeth
Number of subjects: 62
Study: 21875518

Group type: EXPERIMENTAL
Intervention: Nerve mobilization exercises
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conservative treatment (physiotherapy and supportive inserts)
Number of subjects: 28
Study: 19623187

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including nutrition, physical education (PE), and behavior changes with promotional and educational materials.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 17416111

Group type: EXPERIMENTAL
Intervention: AVI-005 (0.5, 1.66 or 5 million international units, MIU)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AVI-005
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (5 MIU of unglycosylated IFN‐alpha2b)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AVI-005 and Control
Number of subjects: 28
Study: 15258011

Group type: EXPERIMENTAL
Intervention: 0.02% Mitomycin C (MMC) for 5 minutes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Limbal Conjunctival Autograft (LCAU)
Number of subjects: 114
Study: 11533345

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/d for 3 days, 0.25 mg/kg/d for 3 days, 0.10 mg/kg/d for 3 days, 0.05 mg/kg/d for 3 days)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 542
Study: 9603589

Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Electromyography (EMG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Xenon anesthesia
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 28
Study: 7817356

Group type: EXPERIMENTAL
Intervention: benazepril 10 mg
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: benazepril 20 mg
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: benazepril 10 mg plus hydrochlorothiazide 12.5 mg
Number of subjects: 814

Group type: COMPARATOR
Intervention: Previous therapy (not specified)
Number of subjects: 814
Study: 29497948

Group type: EXPERIMENTAL
Intervention: Left nasal obstruction (right nostril dominant respiration)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Right nasal obstruction (left nostril dominant respiration)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal sleep (no obstruction)
Number of subjects: 21
Study: 27449771

Group type: EXPERIMENTAL
Intervention: PC patients with germline CDKN2A mutations
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: PC patients without germline CDKN2A mutations
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Overall PC patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CDKN2A− PC patients with family history of digestive system tumors
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CDKN2A+ PC patients
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: CDKN2A− PC patients
Number of subjects: 66
Study: 24932624

Group type: EXPERIMENTAL
Intervention: Corticosteroid spray
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline solution
Number of subjects: 40
Study: 23557500

Group type: EXPERIMENTAL
Intervention: Preservative-free 0.9% sodium chloride solution
Number of subjects: 359

Group type: COMPARATOR
Intervention: Heparin saline solution (10 U/mL)
Number of subjects: 359
Study: 19674282

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: mean on-treatment ribavirin dose >13 mg/kg/day
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: baseline factors (serum HCV RNA <= 400,000 IU/mL, alanine aminotransferase >3 x ULN, non-cirrhotic status, age <= 40 years, white non-Latino ethnicity, body mass index <= 27 kg/m(2))
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: cEVR
Number of subjects: 1550
Study: 19382402

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% ropivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.75% ropivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 mL of 1% ropivacaine
Number of subjects: 90
Study: 16015455

Group type: EXPERIMENTAL
Intervention: Anger imagery induction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Noncontrollable stress
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Relaxation imagery induction
Number of subjects: 80
Study: 12525509

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 796

Group type: COMPARATOR
Intervention: Demographic variables
Number of subjects: 796

Group type: COMPARATOR
Intervention: Mediators of cessation
Number of subjects: 796

Group type: COMPARATOR
Intervention: Psychological support
Number of subjects: 796
Study: 10026388

Group type: EXPERIMENTAL
Intervention: Eptastigmine
Number of subjects: 176

Group type: COMPARATOR
Intervention: Historical untreated controls
Number of subjects: 176
Study: 8660037

Group type: EXPERIMENTAL
Intervention: Intermittent prophylaxis (diazepam at fever)
Number of subjects: 289

Group type: COMPARATOR
Intervention: No prophylaxis (diazepam at seizures)
Number of subjects: 289
Study: 1905630

Group type: EXPERIMENTAL
Intervention: Low protein diet (LPD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal protein intake (NPD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both diets (LPD and NPD)
Number of subjects: 10
Study: 6309116

Group type: EXPERIMENTAL
Intervention: Friendly visitors (FV) and biannual nursing visits
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Biannual nursing (RN) visits only
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 142
Study: 29880563

Group type: EXPERIMENTAL
Intervention: Group self‐management course and usual care
Number of subjects: 703

Group type: COMPARATOR
Intervention: Relaxation and usual care
Number of subjects: 703
Study: 27770454

Group type: EXPERIMENTAL
Intervention: Postoperative total parenteral nutrition (group A; n = 74)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Oral nutrition alone (group B; n = 83)
Number of subjects: 157
Study: 25856933

Group type: EXPERIMENTAL
Intervention: Combination of DMARDs (Methotrexate 15 mg daily and Sulfasalazine 2 gm daily for 3 months) with Intra‐articular Triamcinolone acetate (40 mg per ml) injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: DMARDs (Methotrexate 15 mg daily and Sulfasalazine 2 gm daily for 3 months) alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of DMARDs with Intra‐articular corticosteroids
Number of subjects: 50
Study: 22286314

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 211

Group type: COMPARATOR
Intervention: Fulvestrant 250 mg
Number of subjects: 211
Study: 20150396

Group type: EXPERIMENTAL
Intervention: Visuo-proprioceptive training
Number of subjects: 40
Study: 18327367

Group type: EXPERIMENTAL
Intervention: Intraarticular Hylan G‐F 20 treatment for 3 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraarticular Hylan G‐F 20 treatment plus oral vitamin E for 3 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraarticular Na‐hyaluronate treatment for 5 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Only arthroscopy treatment
Number of subjects: 60
Study: 15681100

Group type: COMPARATOR
Intervention: Control diet A (1.0 x 1/6 of BEE calories)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet B (1.5 x 1/6 of BEE calories)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet C (2.0 x 1/6 of BEE calories)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SBS patients
Number of subjects: 8
Study: 12441905

Group type: EXPERIMENTAL
Intervention: Ozonized autohaemotransfusion
Number of subjects: 20
Study: 10364642

Group type: EXPERIMENTAL
Intervention: APOE genotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 7723645

Group type: COMPARATOR
Intervention: Cadence at 50, 65, 80, 95, 110 rpm and preferred cadence (85.2 +/- 9.2 rpm for cyclists, 91.6 +/- 10.5 rpm for noncyclists)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cadence at 50, 65, 80, 95, 110 rpm and preferred cadence
Number of subjects: 16

Group type: COMPARATOR
Intervention: Preferred cadence
Number of subjects: 16
Study: 2045255

Group type: EXPERIMENTAL
Intervention: Segmental splenectomy and extraperitoneal splenic transposition with gastroesophageal devascularization (S.S.S.T.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Splenectomy and gastroesophageal devascularization
Number of subjects: 30
Study: 6109990

Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alinidine 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoprenaline
Number of subjects: 0
Study: 30617093

Group type: COMPARATOR
Intervention: Benapenem for injection at doses of 62.5, 125, 250, 500, 1,000, 2,000, or 3,000 mg (part A)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Benapenem for injection at doses of 250, 500, or 1,000 mg (part B)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Benapenem for injection at doses of 250, 500, or 1,000 mg once daily for 7 consecutive days (part C)
Number of subjects: 142
Study: 29945735

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation with recruitment maneuver (positive end-expiratory pressure of 15 cm H2O and 20 cm H2O for 2 minutes each)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (noninvasive ventilation with positive end-expiratory pressure of 8 cm H2O)
Number of subjects: 34
Study: 26765325

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study: 25436841

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 22574571

Group type: EXPERIMENTAL
Intervention: Stiletto needle stimulation combined with massage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Massage therapy alone (control group)
Number of subjects: 100
Study: 20222884

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) treatment with two injections, 6 months apart in the gastrocnemius muscle
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (daily stretching programme only)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gait analysis, GMFM‐66, or PEDI
Number of subjects: 15
Study: 18312522

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg x kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg x kg(‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.9% saline (group S)
Number of subjects: 75
Study: 15946418

Group type: EXPERIMENTAL
Intervention: Moderate dose of tea catechins (224 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High dose of tea catechins (674 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (10 mg of tea catechins)
Number of subjects: 9
Study: 12713551

Group type: EXPERIMENTAL
Intervention: 10% glycolic acid (pH 3.5), applied once daily, 6 days per week for 4 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo, applied once daily, 6 days per week for 4 weeks
Number of subjects: 29
Study: 10888287

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Maltodextrins plus aspartame
Number of subjects: 24

Group type: COMPARATOR
Intervention: Maltodextrins
Number of subjects: 24
Study: 9387530

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg q.12.h. for 2 days
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (observed for 2 days before labor induction by PG05 or oxytocin)
Number of subjects: 124
Study: 1492226

Group type: EXPERIMENTAL
Intervention: Etoposide (VP16‐213)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide in combination with amsacrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide in combination with 5‐azacytidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide in combination with anthracycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 0
Study: 3800342

Group type: EXPERIMENTAL
Intervention: Norfloxacin prophylaxis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31556667

Group type: EXPERIMENTAL
Intervention: Immediate treatment (pain management course)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 471
Study: 30001744

Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Fipronil/(S)-methoprene (Frontline Combo® Spot-on Cats)
Number of subjects: 121
Study: 27075027

Group type: EXPERIMENTAL
Intervention: Brief multimodal psychosomatic therapy (BMPT) combined with usual care (UC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 42
Study: 24582273

Group type: EXPERIMENTAL
Intervention: Baseline Framingham Coronary Risk Score (FCRS) of 20% or more
Number of subjects: 4731

Group type: EXPERIMENTAL
Intervention: Novel risk prediction model
Number of subjects: 4731

Group type: EXPERIMENTAL
Intervention: Baseline FCRS of 20% or more
Number of subjects: 4731
Study: 22170375

Group type: EXPERIMENTAL
Intervention: LC-P-LGI diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: LC-CONV diet
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 13
Study: 19930140

Group type: EXPERIMENTAL
Intervention: DTP3 completion among children who were <=60 days old at enrollment
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: DTP3 completion among children living in households with monthly income >Rs. 3000 (US$ 50)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: DTP3 completion among children living <=10 min away from EPI centre
Number of subjects: 378
Study: 17402946

Group type: EXPERIMENTAL
Intervention: 30 degrees lateral position
Number of subjects: 55

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 55
Study: 16230563

Group type: EXPERIMENTAL
Intervention: 200 U of botulinum toxin A
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 100 U of botulinum toxin A
Number of subjects: 43

Group type: COMPARATOR
Intervention: Both doses (100 U and 200 U)
Number of subjects: 43
Study: 12119475

Group type: EXPERIMENTAL
Intervention: L-arginine (12.5 mg.kg(‐1).min(‐1))
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: L-NAME (0.0125 mg.kg(‐1).min(‐1))
Number of subjects: 2
Study: 11233190

Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (Ventak AV II DR)
Number of subjects: 52
Study: 7797033

Group type: EXPERIMENTAL
Intervention: Erythromycin 1.5 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin 3.0 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atropine 6 micrograms.kg-1.h-1 for 30 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 2179277

Group type: EXPERIMENTAL
Intervention: nicardipine 20 mg tid
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 161758

Group type: EXPERIMENTAL
Intervention: Neuraminidase treated allogeneic myeloblasts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neuraminidase treated myeloblasts plus MER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 31720722

Group type: EXPERIMENTAL
Intervention: Home exercise therapy (7 sessions over 12 weeks)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Manual therapy (7 sessions over 12 weeks)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Single session of physiotherapy education (SSPT)
Number of subjects: 615
Study: 31121087

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 16
Study: 28461207

Group type: EXPERIMENTAL
Intervention: Ridinilazole (200 mg every 12 h for 10 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin (125 mg every 6 h for 10 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 100
Study: 25833230

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 57

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 57
Study: 24290848

Group type: EXPERIMENTAL
Intervention: Music-supported training (MST) for the chronic stroke patient
Number of subjects: 1

Group type: COMPARATOR
Intervention: Music training for healthy older adults
Number of subjects: 1
Study: 22282296

Group type: EXPERIMENTAL
Intervention: Proparacaine 0.5% drops (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Proparacaine + 4% lidocaine-soaked cotton tipped swabs (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3.5% lidocaine gel (Group 3)
Number of subjects: 120
Study: 20817301

Group type: EXPERIMENTAL
Intervention: ABRI-1 (number of blood units/(final‐initial hematocrit+0.01))
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: ABRI-2 (number of blood units/(final‐initial hematocrit+0.01))
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Baveno IV criteria without ABRI
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Baveno IV criteria with ABRI-1
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Baveno IV criteria with ABRI-2
Number of subjects: 242
Study: 17197406

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15164895

Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11895066

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 0
Study: 9534831

Group type: EXPERIMENTAL
Intervention: ECT x 3 (three times weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ECT x 2 (twice weekly)
Number of subjects: 0
Study: 7631519

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei GG (LGG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 2716439

Group type: EXPERIMENTAL
Intervention: 150 mg tenilsetam
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 300 mg tenilsetam
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 900 mg tenilsetam
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5 mg co-dergocrine-mesylate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Psychomotor measures
Number of subjects: 15
Study: 7023894

Group type: EXPERIMENTAL
Intervention: 60 mg naltrexone administered thrice weekly
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 120 mg naltrexone administered thrice weekly
Number of subjects: 119
Study: 30375144

Group type: EXPERIMENTAL
Intervention: Medium-dose UVA1 (40-70 J)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical PUVA
Number of subjects: 20
Study: 27677161

Group type: EXPERIMENTAL
Intervention: Gentian violet (0.00165%, BID)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Nystatin oral suspension (500,000 units, QID)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Gentian violet
Number of subjects: 221

Group type: COMPARATOR
Intervention: Nystatin oral suspension
Number of subjects: 221
Study: 26267732

Group type: EXPERIMENTAL
Intervention: Efinaconazole topical solution 10%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0